Next Article in Journal
Carborane-Containing Hydroxamate MMP Ligands for the Treatment of Tumors Using Boron Neutron Capture Therapy (BNCT): Efficacy without Tumor Cell Entry
Next Article in Special Issue
Successful Use of Methylene Blue in Catecholamine-Resistant Septic Shock: A Case Report and Short Literature Review
Previous Article in Journal
Study of Lipophilicity and ADME Properties of 1,9-Diazaphenothiazines with Anticancer Action
Previous Article in Special Issue
Mechanism Repositioning Based on Integrative Pharmacology: Anti-Inflammatory Effect of Safflower in Myocardial Ischemia–Reperfusion Injury
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
IJMS
Volume 24
Issue 8
10.3390/ijms24086972
ijms-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of AT1R/Gαq-Mediated TGF-β1 and ET-1 Signaling

by
Ratchanee Duangrat
1,2,
Warisara Parichatikanond
3,4 and
Supachoke Mangmool
1,*
1
Department of Pharmacology, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
2
Molecular Medicine Graduate Program, Faculty of Science, Mahidol University, Bangkok 10400, Thailand
3
Department of Pharmacology, Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand
4
Centre of Biopharmaceutical Science for Healthy Ageing (BSHA), Faculty of Pharmacy, Mahidol University, Bangkok 10400, Thailand
*
Author to whom correspondence should be addressed.
Int. J. Mol. Sci. 2023, 24(8), 6972; https://doi.org/10.3390/ijms24086972
Submission received: 6 March 2023 / Revised: 30 March 2023 / Accepted: 7 April 2023 / Published: 9 April 2023
(This article belongs to the Special Issue Cardiovascular Pharmacology and Interventions: Future Directions for Cardioprotection 2.0)
Browse Figures
Versions Notes

Abstract

:
Angiotensin II (Ang II) upregulates transforming growth factor-beta1 (TGF-β1) and endothelin-1 (ET-1) in various types of cells, and all of them act as profibrotic mediators. However, the signal transduction of angiotensin II receptor (ATR) for upregulation of TGF-β1 and ET-1, and their effectors that play an essential role in myofibroblast differentiation, are not fully understood. Therefore, we investigated the ATR networking with TGF-β1 and ET-1 and identified the signal transduction of these mediators by measuring the mRNA expression of alpha-smooth muscle actin (α-SMA) and collagen I using qRT-PCR. Myofibroblast phenotypes were monitored by α-SMA and stress fiber formation with fluorescence microscopy. Our findings suggested that Ang II induced collagen I and α-SMA synthesis and stress fiber formation through the AT1R/Gαq axis in adult human cardiac fibroblasts (HCFs). Following AT1R stimulation, Gαq protein, not Gβγ subunit, was required for upregulation of TGF-β1 and ET-1. Moreover, dual inhibition of TGF-β and ET-1 signaling completely inhibited Ang II-induced myofibroblast differentiation. The AT1R/Gαq cascade transduced signals to TGF-β1, which in turn upregulated ET-1 via the Smad- and ERK1/2-dependent pathways. ET-1 consecutively bound to and activated endothelin receptor type A (ETAR), leading to increases in collagen I and α-SMA synthesis and stress fiber formation. Remarkably, dual blockade of TGF-β receptor and ETR exhibited the restorative effects to reverse the myofibroblast phenotype induced by Ang II. Collectively, TGF-β1 and ET-1 are major effectors of AT1R/Gαq cascade, and therefore, negative regulation of TGF-β and ET-1 signaling represents a targeted therapeutic strategy for the prevention and restoration of cardiac fibrosis.

1. Introduction

Cardiac fibrosis is a strong indicator of adverse clinical outcome in heart diseases, including heart failure (HF). In patients with HF, the degree of cardiac fibrosis is correlated with cardiac adverse events and associated with high rates of mortality and morbidity [1,2]. Angiotensin II (Ang II), a major component of the renin-angiotensin system (RAS), is involved in the pathogenesis of cardiac fibrosis by overstimulating angiotensin II receptors (ATRs). Following Ang II stimulation, cardiac fibroblasts undergo transdifferentiation into active myofibroblasts by a process called myofibroblast differentiation [3,4]. Myofibroblast is characterized by overexpression of alpha-smooth muscle actin (α-SMA) and stress fiber formation [5].
Numerous studies have shown that Ang II induced detrimental effects and pathologic changes in cardiac functions mainly through the angiotensin II type 1 receptors (AT1Rs) [4,6]. In contrast, stimulation of angiotensin II type 2 receptors (AT2Rs) exhibited cardioprotective effects, including vasodilating effects and tissue repair [7]. Although the majority of Ang II effects are mediated through AT1R stimulation, the AT2R subtype is also important due to the findings that both subtypes are upregulated in heart diseases [8,9]. ATRs are members of the G protein-coupled receptor (GPCR) superfamily, which couple with the heterotrimeric Gq protein. Binding of Ang II to ATRs leads to activation and dissociation of the Gαq protein from the Gβγ subunit. The activated Gαq protein and Gβγ subunit consequently interact and activate their targeted effectors [10]. However, which subtype of ATRs and subunit of G proteins mediate Ang II-induced myofibroblast differentiation in adult human cardiac fibroblasts (HCFs) have not been comprehensively identified.
The signal transduction of Ang II is complex and involves a series of molecular interactions that transmit the signal from upstream to downstream effectors. Transforming growth factor-beta1 (TGF-β1), a potent profibrotic mediator, has been implicated in ATR signaling. Stimulation of AT1Rs induced TGF-β1 synthesis and secretion in cardiac fibroblasts, and upregulation of TGF-β1 is necessary for Ang II-mediated hypertrophy and fibrosis [11,12]. The canonical Smads and non-canonical mitogen-activated protein kinase (MAPK) proteins are the major downstream effectors of the Ang II/TGF-β1 signaling cascade in the cardiovascular system [12,13]. Furthermore, treatment with TGF-β1 induced endothelin-1 (ET-1) synthesis in vascular endothelial cells [14,15] through the Smad signaling pathway [16]. Administration of losartan, an angiotensin receptor blocker (ARB), resulted in the inhibition of Smad2 and extracellular signal-regulated kinase (ERK) phosphorylation in Loeys–Dietz syndrome mice, contributing to aortic aneurysms [17]. Even though TGF-β1 transduces the signals through Smad- and MAPK-dependent pathways, the precise downstream effectors of TGF-β1 underlying the induction of myofibroblast differentiation needed to be investigated.
A strong correlation between Ang II and endothelin-1 (ET-1) has been demonstrated in previous studies. For instance, Ang II induced ET-1 gene expression [18]. Blockade of endothelin receptor type A (ETAR) abolished Ang II-increased ET-1 contents in aorta and femoral artery [19]. Treatment with losartan inhibited Ang II-induced tissue ET-1 synthesis, suggesting that blockade of AT1R prevents Ang II-induced upregulation of ET-1 [20]. ETRs are classified as GPCRs that have two subtypes, ETAR and ETBR [21]. ET-1 induced myofibroblast differentiation and collagen matrix contraction through the ETARs, but not ETBRs, in lung fibroblasts [22]. Stimulation of ETARs led to the upregulation of collagen deposition in the hearts of hypertensive rats [23]. In addition, both subtypes of ETRs were required for ET-1-induced cell proliferation of lung fibroblasts [24]. However, it remains to be elucidated which ETR subtype is involved in ET-1-induced myofibroblast differentiation of adult HCFs.
Inhibition of TGF-β signaling using anti-TGF-β1 antibody was found to alleviate myocardial fibrosis and cardiac abnormality in pressure-overloaded rat hearts [25]. Moreover, blockade of TGF-β receptor type I (TβRI) diminished TGF-β1-induced collagen synthesis in cardiac fibroblasts and attenuated the progression of myocardial fibrosis in a mouse model of pressure overload [26]. Bosentan, a nonselective ETR antagonist (ERA), has been shown to improve cardiac function, reduce infarct size, and attenuate myocardial fibrosis and remodeling in rats with ischemia/reperfusion injury [27]. Therefore, negative regulation of Ang II, TGF-β1 and ET-1 transmitting signals has been thought to be a potential strategy for inhibition of cardiac fibrosis. Nonetheless, the effects of TβRI/II inhibitor and ERA on the inhibition of Ang II-induced myofibroblast differentiation in adult HCFs are unknown.
So far, many HF patients have been reported to receive clinical attention only after significant fibrosis has already occurred. Therefore, the reversal of the myofibroblast phenotype may serve as a means to delay the pathological features of cardiac fibrosis. In the present study, we also investigated the restorative effects of valsartan, LY2109761 (TβRI/II inhibitor), and bosentan on myofibroblast differentiation induced by Ang II. The essential roles of TGF-β1, ET-1, and Ang II networking and identification of signal transduction of these profibrotic mediators will assist us in discovering therapeutic strategies for the treatment and prevention of cardiac fibrosis.

2. Results

2.1. Treatment with Ang II, TGF-β1, or ET-1 Promotes Myofibroblast Differentiation in a Dose-Dependent Manner in Adult Human Cardiac Fibroblasts (HCFs)

In this study, we first determined the effects of Ang II, TGF-β1, and ET-1 on myofibroblast differentiation by measuring collagen I and α-SMA expression and stress fiber formation. Treatment with Ang II, TGF-β1, or ET-1 induced the synthesis of collagen I and α-SMA in a dose-dependent manner with maximal effects observed at 200 nM, 1 ng/mL, and 20 nM, respectively (Supplementary Figure S1A,B). Furthermore, treatment of adult HCFs with these profibrotic mediators resulted in a significant increase in stress fiber formation, as shown in the red color, in a dose-dependent fashion (Supplementary Figure S1C). Our results suggested that Ang II, TGF-β1, and ET-1 have the ability to induce the transdifferentiation of fibroblasts into myofibroblasts in adult HCFs.

2.2. Ang II Induces Myofibroblast Differentiation through AT1R/Gαq Axis

Next, we aimed to identify the signal transduction of ATRs responsible for Ang II-induced myofibroblast differentiation in adult HCFs. Pretreatment with valsartan (AT1R antagonist) completely blocked Ang II-induced overexpression of collagen I and α-SMA as well as stress fiber formation (Figure 1A–C). AT1R is a Gq protein-coupled receptor (GqPCR) that transduces its signal through both Gαq and Gβγ subunits [10]. We applied FR900359 (Gαq inhibitor) and gallein (Gβγ inhibitor) to investigate which subunits of the G protein play an essential role in AT1R-mediated fibrogenic effects and found that pretreatment with FR900359 inhibited Ang II-induced myofibroblast differentiation, while blockade of Gβγ activity using gallein did not interfere with Ang II actions (Figure 1A–C). Together, these findings indicated that Ang II exerts fibrogenic effects in AT1R-dependent activation of Gαq protein.

2.3. Dual Blockade of TGF-β Receptor and Endothelin Receptor Inhibits Ang II-Induced Myofibroblast Differentiation

TGF-β1 and ET-1 are downstream effectors of Ang II and have been associated with ATR signaling. In rat aorta, Ang II induced the upregulation of TGF-β1 [11] and ET-1 protein expression [20]. Next, we used LY2109761 (TβRI/II inhibitor) and bosentan (ETR antagonist; ERA) to investigate the contributions of TGF-β1 and ET-1 to Ang II-induced myofibroblast differentiation. As shown in Figure 2, blockade of TGF-β signaling with LY2109761 suppressed Ang II-induced collagen I and α-SMA synthesis and stress fiber formation. However, LY2109761 had less inhibitory effects than valsartan. In addition, blockade of ETR signaling using bosentan did not show significant preventive effects on Ang II-induced myofibroblast differentiation. Interestingly, cotreatment of LY2109761 with bosentan completely reduced fibrogenic effects of Ang II, which had an inhibitory effect similar to those of valsartan (Figure 2A–C). These results suggested that ET-1 appears to function synergistically with TGF-β1 to promote myofibroblast differentiation induced by Ang II. Thus, dual blockade of TGF-β and ET-1 is required to prevent Ang II-induced myofibroblast differentiation in adult HCFs.

2.4. Blockade of ETRs, Not ATRs, Inhibits TGF-β1-Induced Myofibroblast Differentiation

ET-1 is necessary to complete Ang II-mediated cardiac hypertrophy [28]. TGF-β and ET-1 cooperate in the pathophysiology of lung fibrosis [29]. Thus, Ang II-mediated ATR signaling is complex and involved in a cascade of molecular interactions of TGF-β1 and ET-1. As shown in Figure 3, blockade of ETRs using bosentan significantly inhibited TGF-β1-induced collagen I and α-SMA synthesis and stress fiber formation. In contrast, blockade of ATRs with valsartan did not attenuate profibrotic effects of TGF-β1 (Figure 3A–C). These results indicated that TGF-β1 is an important downstream effector of ATRs and exerts fibrotic effects through ETR signaling to drive the transformation of fibroblasts into myofibroblasts. Hence, ET-1 is a downstream effector of TGF-β signaling.

2.5. Smad and ERK Are Required for TGF-β1-Induced Myofibroblast Differentiation in Adult HCFs

The canonical Smad-dependent pathway and non-canonical MAPK-dependent pathway have been implicated in TGF-β signaling and have been shown to contribute to the development of fibrosis in various tissues [30]. Therefore, we investigated whether these targeted proteins of TGF-β1 signaling are involved in the regulation of myofibroblast differentiation in adult HCFs by using the specific inhibitors SIS3 (Smad3 inhibitor), FR180204 (ERK1/2 inhibitor), and SB203580 (p38 MAPK inhibitor). Pretreatment with either SIS3 or FR180204 significantly suppressed TGF-β1-induced overexpression of collagen I and α-SMA, including stress fiber formation (Figure 3D–F). Contrarily, pretreatment with SB203580 did not show inhibitory effects on TGF-β1-mediated myofibroblast differentiation. Interestingly, dual inhibition of Smad3 and ERK1/2 activities completely blocked these TGF-β1 effects (Figure 3D–F). Hence, TGF-β1 transduces fibrogenic signaling through canonical Smad and noncanonical ERK1/2 cascades in adult HCFs.

2.6. ET-1 Is a Downstream Effector of Ang II/TGF-β Axis That Stimulates Myofibroblast Differentiation via the ETAR Subtype in Adult HCFs

TGF-β induced ET-1 synthesis in vascular endothelial cells [14,15] and blockade of ETARs abolished Ang II-increased ET-1 contents in aorta and femoral artery [19]. Thus, ET-1 is a downstream effector of Ang II and TGF-β1 in the vascular system. We further tested whether ET-1 acts as a downstream effector of the Ang II/TGF-β axis in myofibroblast differentiation in adult HCFs. We found that the antagonism of ETR with bosentan completely suppressed ET-1-stimulated α-SMA and collagen I synthesis and stress fiber formation (Figure 4A–C). Blockades of either TGF-β receptors with LY2109761 or ATRs with valsartan did not inhibit the profibrotic effects of ET-1 (Figure 4A–C), indicating that ET-1 serves as a downstream effector of ATR and TGF-β receptor signaling.
In addition, ET-1 binds to ETRs, including ETAR and ETBR, and exerts its effects on tissue fibrosis [31]. Here, we also determined the subtype specificity of ETRs in ET-1-induced myofibroblast differentiation in adult HCFs. Pretreatment of fibroblasts with ambrisentan (ETAR antagonist), but not BQ788 (ETBR antagonist), was able to antagonize ET-1-induced α-SMA and collagen I synthesis and stress fiber formation (Figure 4D–F). Collectively, ET-1 acts as a downstream target of the Ang II/TGF-β1 cascade by binding to and activating the ETAR subtype to promote myofibroblast differentiation.

2.7. Gαq-Dependent Activation of AT1Rs Is Necessary for the Upregulation of TGF-β1 and ET-1 in Adult HCFs

TGF-β1 and ET-1 are the important effectors of ATR signaling; however, the subtype specificity of ATR on upregulation of TGF-β1 and ET-1 is unknown. We found that AT1R antagonism with valsartan completely abolished Ang II-induced secretion and synthesis of TGF-β1 and ET-1, whereas PD123319 had no effect on Ang II-mediated upregulation of TGF-β1 and ET-1 (Figure 5A,B). In addition, blockade of Gαq protein signaling with FR900359 significantly inhibited Ang II-mediated secretion (Figure 5A) and synthesis (Figure 5B) of TGF-β1 and ET-1. Moreover, pretreatment with LY2109761 (TβRI/II inhibitor) significantly suppressed Ang II-induced upregulation of ET-1 (Figure 5), indicating that the AT1R/TGF-β cascade is essential for ET-1 upregulation. Therefore, the AT1R/Gαq axis is necessary for upregulation of TGF-β1 and ET-1 in adult HCFs.

2.8. TGF-β1-Induced Upregulation of ET-1 Is Dependent of Smad and ERK1/2 in Adult HCFs

Since TGF-β-induced ET-1 mRNA expression is dependent of Smad proteins in vascular endothelial cells [16], we next examined the possible role of downstream mediators of TGF-β signaling on upregulation of ET-1 in adult HCFs. The secretion and synthesis of ET-1 potentially increased following TGF-β1 stimulation. In contrast, TGF-β1-mediated ET-1 upregulation was attenuated in the presence of either SIS3 (Smad inhibitor) or FR180204 (ERK1/2 inhibitor), while inhibition of p38 MAPK had no effect (Figure 6). These results demonstrated that TGF-β1 induces upregulation of ET-1 through the canonical Smad-dependent and non-canonical ERK1/2-dependent pathways in adult HCFs.

2.9. The Reversibility of Ang II-Induced Myofibroblast Differentiation by Dual Inhibition of TGF-β Receptor and ETR

Once cardiac fibrosis has already occurred, the reversal of myofibroblast differentiation is considered as a potential strategy to suppress the progression of cardiac fibrosis [32]. In this study, we investigated the effects of valsartan (ATR antagonist), LY2109761 (TβRI/II inhibitor), bosentan (ETR antagonist), and LY2109761 plus bosentan on the reversibility of myofibroblast differentiation induced by Ang II. Firstly, adult HCFs were incubated with Ang II (200 nM) for 24 h to induce fibroblast-to-myofibroblast transformation, which is characterized by α-SMA overexpression and actin stress fiber formation. After Ang II incubation and changing the culture medium, cells were co-treated with Ang II with vehicle, valsartan, LY2109761, bosentan, or LY2109761 plus bosentan, and cultured for up to 3 days. The assessments of α-SMA expression and stress fiber formation were performed on day 1 and day 3 of treatment (Figure 7A). In the absence of inhibitors (Ang II + vehicle group), Ang II induced an increase in α-SMA levels and stress fiber formation for up to 3 days of observation (Figure 7B,C). The 1-day incubation of all inhibitors was insufficient to reverse myofibroblast differentiation. However, on day 3 of observation, α-SMA-positive myofibroblasts and stress fiber formation were dramatically attenuated in the presence of either valsartan or LY2109761 (Figure 7B,C). Moreover, a combination of TβRI/II inhibitor with ERA reversed the myofibroblast phenotype, as demonstrated by a reduction in α-SMA expression and stress fiber formation (Figure 7B,C). The potency of dual inhibition of TGF-β receptor and ETR in the reversal of myofibroblasts was similar to that of valsartan. These data implied that dual blockade of TGF-β and ET-1 signaling can reverse Ang II-induced myofibroblast differentiation in adult HCFs.

3. Discussion

The transdifferentiation of fibroblasts into myofibroblasts is a key cellular mechanism in the heart that drives the fibrotic responses and ultimately contributes to myocardial fibrosis [32]. Myofibroblasts are smooth muscle-like active fibroblasts that overexpress α-SMA, contain large bundles of actin microfilaments organized into prominent stress fibers, and are the major source of ECM proteins in fibrotic hearts [5,33]. Regardless of the pathology of fibrosis, myofibroblast differentiation is a hallmark of the fibrotic response; therefore, agents capable of interrupting the transformation process could potentially prevent maladaptive tissue fibrosis and remodeling in response to profibrotic stimuli such as Ang II, TGF-β1, and ET-1.
Stimulation of AT1Rs by Ang II promoted interstitial fibrosis, contributing to ventricle wall stiffness and cardiac dysfunction [6]. Contrarily, blockade of AT1Rs by ARBs resulted in the alleviation of cardiac fibrosis in rat models of pressure overload or myocardial infarction [34,35]. Consistent with these animal studies, our present study demonstrated that Ang II stimulates myofibroblast differentiation, as determined by collagen I and α-SMA overexpression, as well as stress fiber formation, in a dose-dependent manner via the AT1R subtype in adult HCFs. Antagonism of AT1Rs with valsartan prevented the fibrogenic effects of Ang II. AT1R stimulation leads to G protein coupling and dissociation of Gαq protein from Gβγ subunit [10]. Our previous study demonstrated that AT1R mediated upregulation of growth factors through Gαq protein, not Gαi or Gα12/13 proteins [11]. In addition, Gβγ subunit of ATRs is also known to regulate the activities of targeted proteins. For instance, Ang II stimulated the Janus kinase 2/signal transducers and activators of transcription (JAK2/STAT) signaling via the Gβγ subunit in rat aortic smooth muscle cells [36]. In our present study, blockade of Gαq protein inhibited Ang II-induced myofibroblast differentiation, while blockade of Gβγ activity did not inhibit Ang II actions, emphasizing that the AT1R/Gαq axis is necessary for the fibrogenic effects of Ang II in adult HCFs.
TGF-β1 has been described as an essential mediator of RAS and plays an important role in the pathogenesis of remodeling heart. In TGF-β1 deficient mice, administration of Ang II did not promote myocardial fibrosis and hypertrophy [37]. Moreover, Ang II induced TGF-β1 expression in cardiac myocytes and fibroblasts, and upregulation of TGF-β1 was required for Ang II-induced hypertrophy [11,12]. In line with previous studies, blockade of TGF-β signaling with LY2109761 (TβRI/II inhibitor) significantly inhibited Ang II-induced myofibroblast differentiation. However, LY2109761 showed less inhibitory effects than valsartan. Thus, TGF-β1 is one of the downstream effectors of Ang II and acts as an important part of ATR signaling. TGF-β receptors are divided into two subtypes: TGF-β receptor type I (TβRI, or called ALK5) and type II (TβRII) [33]. TGF-β1 activates fibroblasts and other cells (e.g., epithelial cells, endothelial cells, and pericytes) to form myofibroblasts via two major signaling pathways, namely the canonical Smad-dependent and non-canonical MAPK-dependent pathways [33,38]. Ang II-induced collagen synthesis required TGF-β/Smad and MAPK signaling [39]. In addition, activation of ERK1/2 by Ang II is dependent on TGF-β [11]. The findings from our study demonstrated that inhibition of either Smad3 or ERK1/2 activities attenuate TGF-β1-stimulated myofibroblast differentiation. Therefore, TGF-β1 mediated myofibroblast transdifferentiation of adult HCFs through the Smad and ERK1/2 cascades.
ET-1 is one of the key players in the initiation and maintenance of tissue fibrosis and the effects of Ang II are partially mediated through the action of ET-1. ET-1 secreted from endothelial cells was required for Ang II-induced myocardial hypertrophy and fibrosis [28]. In addition, treatment with losartan prevented an increase in aorta ET-1 content induced by Ang II [20]. Our results showed that blockade of ET-1 signaling using bosentan alone tends to reduce Ang II-induced myofibroblast differentiation. Interestingly, dual antagonisms of ETR and TGF-β receptor signaling by co-treatment with bosentan and LY2109761 (TβR I/II inhibitor) potentially inhibited Ang II actions, exhibiting inhibitory potency similar to that of valsartan. Our data indicated that ET-1 appears to function synergistically with TGF-β1 to promote myofibroblast differentiation induced by Ang II. TGF-β and ET-1 have cooperative functions in the vascular system, particularly in endothelial cells. Despite these findings, the precise nature of the interaction between TGF-β and ET-1 in human cardiac fibroblasts remains incompletely understood. Our study demonstrated that ET-1, but not Ang II, is a downstream effector of TGF-β1 signaling. In addition, Ang II, TGF-β1, and ET-1 did not act independently from each other, but synchronously acted as part of a complex signaling network to induce myofibroblast differentiation.
ET-1 is upregulated in hypertensive hearts, and the endothelin system played a critical role in the development of hypertrophy and fibrosis in a rat model of HF [40]. Although the detrimental effects of ET-1 are mostly mediated via ETAR, ETBR may play a part in the pathophysiological event of cardiac fibrosis since ETBRs were detected to be upregulated in fibrotic-related diseases such as scleroderma-associated fibrotic lung disease [41] and pulmonary arterial hypertension [42]. Here, we demonstrated that ET-1-induced myofibroblast differentiation is suppressed by antagonism of ETARs, highlighting the role of ETARs in activation of human HCFs.
There are several lines of evidence regarding the relationship between the RAS, TGF-β signaling, and endothelin system. For instance, Ang II mediated myocardial fibrosis by upregulating TGF-β1 synthesis in infarcted rat hearts [43]. Ang II induced mRNA expression of preproendothelin-1 [44] and increased the release of the mature ET-1 peptide in vascular smooth muscle cells [45]. Here, we demonstrated that Ang II induces synthesis and secretion of TGF-β1 and ET-1 through the AT1R/Gαq cascade. We also found that TGF-β1 is required for Ang II-induced ET-1 synthesis in adult HCFs. TGF-β1 potentially induced ET-1 upregulation, which required the cooperation of Smads and activator protein 1 (AP-1) in vascular endothelial cells [16]. On the other hand, another study reported that TGF-β-induced ET-1 production occurs through a Smad-independent ALK5/JNK/AP-1-dependent pathway in normal and fibrotic human lung fibroblasts [46]. Our findings provided evidence that TGF-β1 induces ET-1 synthesis and secretion in adult HCFs through both Smad-dependent and ERK1/2-dependent pathways, while Smad and ERK1/2 are likely involved in the upregulation of ET-1. Thus, further investigation is needed to fully understand the mechanisms and complexities of these pathways.
Prevention of myofibroblast differentiation by using specific inhibitors for signaling molecules has shown advantages in antifibrotic events. Previous studies demonstrated that myofibroblast differentiation could be reversed with anti-fibrotic agents such as prostaglandin E2 [47], metformin [48], and ERAs (ambrisentan and bosentan) [49]. As shown in this study, treatment with either valsartan or LY2109761 (TβRI/II inhibitor) promoted dedifferentiation of myofibroblasts after day 3 of treatment with reductions in α-SMA expression and stress fiber formation, emphasizing the restorative effects of ARB and TβRI/II inhibitor. However, treatment with bosentan alone could not show a significant reversal of this differentiated phenotype. Remarkably, dual inhibition of TGF-β receptor and ETR showed more efficacy in the reversibility of myofibroblast differentiation compared to TβRI/II inhibitor alone, highlighting current therapeutic strategies for limiting cardiac fibrosis, highlighting current trends in the approach to attenuating cardiac fibrosis. One limitation is that our results derived from in vitro experiments. Therefore, further investigations are necessary to explore the preventive and restorative effects of these specific inhibitors in animal models of fibrosis.

4. Materials and Methods

4.1. Reagents

Ang II, ET-1, PD123319, gallein (Gβγ inhibitor), and BQ788 were obtained from Tocris Bioscience (Ellisville, MO, USA). Recombinant human TGF-β1, valsartan, bosentan, ambrisentan, LY2109761, FR180204, and SB203580 were obtained from Sigma Aldrich (Saint Louis, MO, USA). SIS3 (Smad3 inhibitor) and FR900359 (Gαq inhibitor) were obtained from Cayman Chemical (Ann Arbor, MI, USA). Fibroblast growth medium and related cell culture reagents were obtained from Promocell (Heidelberg, Germany).

4.2. Fibroblast Cultures

Adult HCFs were obtained from Promocell (catalogue number C-12375). Cells were cultured in fibroblast growth medium and incubated at 37 °C in a humidified incubator containing 5% CO2. Fibroblasts from the second to fourth passages were used for all assays.

4.3. Immunofluorescence Staining for the Detection of α-SMA Expression

Adult HCFs (1 × 104 cells/well) were seeded onto gelatin-coated cover slips in 12-well plates, and cells were allowed to attach overnight. After treatment, cells were fixed with 4% paraformaldehyde at 4 °C overnight. Cells were permeabilized by 0.1% Triton X-100 solution and blocked with 2% bovine serum albumin (BSA) for 1 h. Cells were then incubated with antibody against α-SMA (1:500, Sigma Aldrich), diluted in blocking buffer for 1 h and incubated with Alexa Fluor 488 secondary antibody (1:250, Invitrogen; Carlsbad, CA, USA) for 1 h. After washing with phosphate buffered saline (PBS), cells were mounted with antifade mounting medium containing 4′,6-diamidino-2-phenylindole (DAPI) (Invitrogen) [50]. The images were captured at 20× magnification by fluorescence microscope at wavelengths of 488/520 nm (Nikon Eclipse Ts2R; Tokyo, Japan). Three to five images with non-overlapping areas were taken per each treatment group. The mean fluorescence intensity was analyzed using Image J software (version 1.53k, NIH, Bethesda, MD, USA).

4.4. Immunofluorescence Staining for Detection of Actin Stress Fiber

Fluorescent-labeled phalloidin was used for detection of actin stress fiber in the cells. Fibroblasts (1 × 104 cells/well) were seeded on gelatin-coated cover slips in 12-well plates overnight. After treatment, cells were fixed with 4% paraformaldehyde at 4 °C overnight. A 0.1% Triton X-100 solution was used to permeabilize the cells, and 2% BSA was further added to block the cells for 1 h. Cells were incubated with Alexa Fluor 594 phalloidin (1:100, Invitrogen) for 1 h and washed with PBS. An antifade mounting medium containing DAPI (Invitrogen) was used to mount the cells. The images were captured at 20× magnification by fluorescence microscope at wavelengths of 581/609 nm (Nikon Eclipse Ts2R). Three to five images with non-overlapping areas were taken per each treatment group. The mean fluorescence intensity was analyzed using ImageJ software (version 1.53k, NIH, Bethesda, MD, USA).

4.5. Quantitative Real-Time RT-PCR

Total RNA was extracted from fibroblasts using GeneJET RNA isolation kits (Thermo scientific, Waltham, MA, USA). The quantitation of mRNA expression was analyzed using real-time qPCR. Amplification reactions were performed using AriaMx Real Time PCR system and Brilliant III ultra-fast SYBR green qRT-PCR master mix (Agilent Technologies, Santa Clara, CA, USA). The isolation of total RNA and real-time qRT-PCR were performed as previously described [51]. All primer sequences were obtained from Macrogen (Seoul, Republic of Korea). The mRNA expression of COL1A1, α-SMA, TGF-β1, and ET-1 was determined using primers as described: COL1A1 (sense, 5′-CTGCTGGACGTCCTGGTG AA-3′; antisense, 5′-ACGCTGTCCAGCAATACCTTGAG-3′), α-SMA (sense, 5′-TGGCTATTCCTTCGTTACTACTGCT-3′; antisense, 5′-CATCAGGCAACTCGTAACTCTTCTC-3′), TGF-β1 (sense, 5′-CCCAGCATCTGCAAAGCTC-3′; antisense, 5′- GTCAATGTACAG CTGCCGCA-3′), and ET-1 (sense, 5′-GACATCATTTGGGTCAACACTC-3′; antisense, 5′-GGC ATCTATTTTCACGGTCTGT-3′). The ratio of the mRNA of interest was normalized with β-actin (sense, 5′-GTGGCCGAGGACTTTGATTG-3′; antisense, 5′-AGTGGGGTGGC TTTTAGGATG-3′). Relative gene expression was determined by the 2−ΔΔCT method.

4.6. Enzyme-Linked Immunosorbent Assays (ELISA)

Adult HCFs (5 × 105 per/well in 6-well plate) were treated with specific reagents in serum-free medium for 24 h. After treatment, the culture medium was collected and stored at −80 °C for further use. The levels of TGF-β1 and ET-1 in the culture medium were measured by ELISA (TGF-β1 ELISA kit, ab100647; ET-1 ELISA kit, ab133030 from Abcam). Briefly, 100 μL of each standard and each sample (culture medium) was added to the appropriate wells as previously described [52]. After the end of reaction, samples were immediately measured for absorbance at specific wavelengths using an EZ Read 400 microplate reader (Biochrom, Cambridge, UK). The amounts of TGF-β1 and ET-1 in the culture medium were calculated using the standard curve as described in the manufacturer’s instructions.

4.7. Quantification and Statistical Analysis

Data are presented as the mean ± SEM of 4 independent experiments. The statistical differences were analyzed by one-way ANOVA with Tukey’s post hoc test for comparisons of three or more groups and Student’s t-test for two groups. A p value below 0.05 (p < 0.05) was considered statistically significant. Statistical analysis was performed with GraphPad Prism (version 6.0).

5. Conclusions

In summary, our data supported a concept whereby TGF-β1 and ET-1 are required for AT1R-stimulated myofibroblast differentiation in adult HCFs. Ang II induced myofibroblast differentiation via the AT1R/Gαq cascade (Figure 8). The activated AT1Rs transduced the signal through TGF-β1 cascade and consequently upregulated ET-1 via the Smad-dependent and ERK1/2-dependent pathways. Thus, TGF-β1 and ET-1 are downstream effectors of Ang II and act as part of the ATR signaling and network for myofibroblast differentiation. Interestingly, dual antagonism of TGF-β receptor and ETR could prevent and reverse the myofibroblast phenotype induced by Ang II. This study reported on a novel therapeutic strategy for the prevention and restoration of Ang II-mediated cardiac fibrosis.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms24086972/s1.

Author Contributions

Conceptualization, W.P. and S.M.; methodology, R.D., W.P. and S.M.; validation, R.D., W.P. and S.M.; formal analysis, R.D., W.P. and S.M.; investigation, S.M.; resources, W.P. and S.M.; data curation, R.D., W.P. and S.M.; writing—original draft preparation, R.D.; writing—review and editing, W.P. and S.M.; visualization, R.D. and S.M.; supervision, S.M.; project administration, S.M.; funding acquisition, R.D., W.P. and S.M. All authors have read and agreed to the published version of the manuscript.

Funding

This research was funded by grants from the National Research Council of Thailand (NRCT) and Mahidol University (Grant number NRCT5-RSA63015-07) (to S.M.); the Science Achievement Scholarship of Thailand (SAST) from Office of the Higher Education Commission (OHEC) (to R.D.); and Mahidol University under the New Discovery and Frontier Research Grant (Grant number NDFR 32/2564) (to W.P.).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Raw data presented in this study are available on request from the corresponding author.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Aoki, T.; Fukumoto, Y.; Sugimura, K.; Oikawa, M.; Satoh, K.; Nakano, M.; Nakayama, M.; Shimokawa, H. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure-Comparison between preserved and reduced ejection fraction heart failure. Circ. J. 2011, 75, 2605–2613. [Google Scholar] [CrossRef] [Green Version]
  2. Kato, S.; Saito, N.; Kirigaya, H.; Gyotoku, D.; Iinuma, N.; Kusakawa, Y.; Iguchi, K.; Nakachi, T.; Fukui, K.; Futaki, M.; et al. Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int. J. Cardiol. 2015, 191, 314–319. [Google Scholar] [CrossRef] [PubMed]
  3. Kawano, H.; Do, Y.S.; Kawano, Y.; Starnes, V.; Barr, M.; Law, R.E.; Hsueh, W.A. Angiotensin II has multiple profibrotic effects in human cardiac fibroblasts. Circulation 2000, 101, 1130–1137. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  4. Murphy, A.M.; Wong, A.L.; Bezuhly, M. Modulation of angiotensin II signaling in the prevention of fibrosis. Fibrogenesis Tissue Repair 2015, 8, 7. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  5. Kurose, H.; Mangmool, S. Myofibroblasts and inflammatory cells as player of cardiac fibrosis. Arch. Pharm. Res. 2016, 39, 1100–1113. [Google Scholar] [CrossRef] [PubMed]
  6. Schnee, J.M.; Hsueh, W.A. Angiotensin II, adhesion, and cardiac fibrosis. Cardiovasc. Res. 2000, 46, 264–268. [Google Scholar] [CrossRef] [PubMed] [Green Version]
  7. Matavelli, L.C.; Siragy, H.M. AT2 receptor activities and pathophysiological implications. J. Cardiovasc. Pharmacol. 2015, 65, 226. [Google Scholar] [CrossRef] [Green Version]
  8. Lopez, J.; Lorell, B.; Ingelfinger, J.; Weinberg, E.; Schunkert, H.; Diamant, D.; Tang, S.S. Distribution and function of cardiac angiotensin AT1-and AT2-receptor subtypes in hypertrophied rat hearts. Am. J. Physiol. Heart Circ. Physiol. 1994, 267, H844–H852. [Google Scholar] [CrossRef]
  9. Tsutsumi, Y.; Matsubara, H.; Ohkubo, N.; Mori, Y.; Nozawa, Y.; Murasawa, S.; Kijima, K.; Maruyama, K.; Masaki, H.; Moriguchi, Y.; et al. Angiotensin II type 2 receptor is upregulated in human heart with interstitial fibrosis, and cardiac fibroblasts are the major cell type for its expression. Circ. Res. 1998, 83, 1035–1046. [Google Scholar] [CrossRef] [Green Version]
  10. Forrester, S.J.; Booz, G.W.; Sigmund, C.D.; Coffman, T.M.; Kawai, T.; Rizzo, V.; Scalia, R.; Eguchi, S. Angiotensin II signal transduction: An update on mechanisms of physiology and pathophysiology. Physiol. Rev. 2018, 98, 1627–1738. [Google Scholar] [CrossRef]
  11. Duangrat, R.; Parichatikanond, W.; Morales, N.P.; Pinthong, D.; Mangmool, S. Sustained AT1R stimulation induces upregulation of growth factors in human cardiac fibroblasts via Gαq/TGF-β/ERK signaling that influences myocyte hypertrophy. Eur. J. Pharmacol. 2022, 937, 175384. [Google Scholar] [CrossRef]
  12. Rosenkranz, S. TGF-β1 and angiotensin networking in cardiac remodeling. Cardiovasc. Res. 2004, 63, 423–432. [Google Scholar] [CrossRef] [Green Version]
  13. Flores-Vergara, R.; Olmedo, I.; Aránguiz, P.; Riquelme, J.A.; Vivar, R.; Pedrozo, Z. Communication between cardiomyocytes and fibroblasts during cardiac ischemia/reperfusion and remodeling: Roles of TGF-β, CTGF, the renin angiotensin axis, and non-coding RNA molecules. Front. Physiol. 2021, 12, 716721. [Google Scholar] [CrossRef]
  14. Kurihara, H.; Yoshizumi, M.; Sugiyama, T.; Takaku, F.; Yanagisawa, M.; Masaki, T.; Hamaoki, M.; Kato, H.; Yazaki, Y. Transforming growth factor-β stimulates the expression of endothelin mRNA by vascular endothelial cells. Biochem. Biophys. Res. Commun. 1989, 159, 1435–1440. [Google Scholar] [CrossRef]
  15. Lee, S.D.; Lee, D.S.; Chun, Y.G.; Paik, S.H.; Kim, W.S.; Kim, D.S.; Kim, W.D.; Tuder, R.M.; Voelkel, N.F. Transforming growth factor-β1 induces endothelin-1 in a bovine pulmonary artery endothelial cell line and rat lungs via cAMP. Pulm. Pharmacol. Ther. 2000, 13, 257–265. [Google Scholar] [CrossRef]
  16. Rodríguez-Pascual, F.; Reimunde, F.M.; Redondo-Horcajo, M.; Lamas, S. Transforming growth factor-β induces endothelin-1 expression through activation of the Smad signaling pathway. J. Cardiovasc. Pharmacol. 2004, 44, S39–S42. [Google Scholar] [CrossRef]
  17. Gallo, E.M.; Loch, D.C.; Habashi, J.P.; Calderon, J.F.; Chen, Y.; Bedja, D.; van Erp, C.; Gerber, E.E.; Parker, S.J.; Sauls, K.; et al. Angiotensin II–dependent TGF-β signaling contributes to Loeys-Dietz syndrome vascular pathogenesis. J. Clin. Invest. 2014, 124, 448–460. [Google Scholar] [CrossRef] [Green Version]
  18. Cheng, T.H.; Cheng, P.Y.; Shih, N.L.; Chen, I.B.; Wang, D.L.; Chen, J.J. Involvement of reactive oxygen species in angiotensin II-induced endothelin-1 gene expression in rat cardiac fibroblasts. J Am. Coll. Cardiol. 2003, 42, 1845–1854. [Google Scholar] [CrossRef] [Green Version]
  19. Barton, M.; Shaw, S.; Moreau, P.; Lüscher, T.F. Angiotensin II increases vascular and renal endothelin-1 and functional endothelin converting enzyme activity in vivo: Role of ETA-receptors for endothelin regulation. Biochem. Biophys. Res. Commun. 1997, 238, 861–865. [Google Scholar] [CrossRef]
  20. d’Uscio, L.V.; Shaw, S.; Barton, M.; Lüscher, T.F. Losartan but not verapamil inhibits angiotensin II–induced tissue endothelin-1 increase: Role of blood pressure and endothelial function. Hypertension 1998, 31, 1305–1310. [Google Scholar] [CrossRef] [Green Version]
  21. Davenport, A.P.; Hyndman, K.A.; Dhaun, N.; Southan, C.; Kohan, D.E.; Pollock, J.S.; Pollock, D.M.; Webb, D.J.; Maguire, J.J. Endothelin. Pharmacol. Rev. 2016, 68, 357–418. [Google Scholar] [CrossRef] [Green Version]
  22. Shi-Wen, X.; Chen, Y.; Denton, C.P.; Eastwood, M.; Renzoni, E.A.; Bou-Gharios, G.; Pearson, J.D.; Dashwood, M.; du Bois, R.M.; Black, C.M.; et al. Endothelin-1 promotes myofibroblast induction through the ETA receptor via a rac/phosphoinositide 3-kinase/Akt-dependent pathway and is essential for the enhanced contractile phenotype of fibrotic fibroblasts. Mol. Biol. Cell 2004, 15, 2707–2719. [Google Scholar] [CrossRef] [Green Version]
  23. Ammarguellat, F.; Larouche, I.; Schiffrin, E.L. Myocardial fibrosis in DOCA-salt hypertensive rats: Effect of endothelin ETA receptor antagonism. Circulation 2001, 103, 319–324. [Google Scholar] [CrossRef] [Green Version]
  24. Cambrey, A.D.; Harrison, N.K.; Dawes, K.E.; Southcott, A.M.; Black, C.M.; du Bois, R.M.; Laurent, G.J.; McAnulty, R.J. Increased levels of endothelin-1 in bronchoalveolar lavage fluid from patients with systemic sclerosis contribute to fibroblast mitogenic activity in vitro. Am. J. Respir. Cell Mol. Biol. 1994, 11, 439–445. [Google Scholar] [CrossRef]
  25. Kuwahara, F.; Kai, H.; Tokuda, K.; Kai, M.; Takeshita, A.; Egashira, K.; Imaizumi, T. Transforming growth factor-β function blocking prevents myocardial fibrosis and diastolic dysfunction in pressure-overloaded rats. Circulation 2002, 106, 130–135. [Google Scholar] [CrossRef] [Green Version]
  26. Engebretsen, K.V.; Skårdal, K.; Bjørnstad, S.; Marstein, H.S.; Skrbic, B.; Sjaastad, I.; Christensen, G.; Bjørnstad, J.L.; Tønnessen, T. Attenuated development of cardiac fibrosis in left ventricular pressure overload by SM16, an orally active inhibitor of ALK5. J. Mol. Cell. Cardiol. 2014, 76, 148–157. [Google Scholar] [CrossRef]
  27. Singh, A.D.; Amit, S.; Kumar, O.S.; Rajan, M.; Mukesh, N. Cardioprotective effects of bosentan, a mixed endothelin type A and B receptor antagonist, during myocardial ischaemia and reperfusion in rats. Basic. Clin. Pharmacol. Toxicol. 2006, 98, 604–610. [Google Scholar] [CrossRef]
  28. Adiarto, S.; Heiden, S.; Vignon-Zellweger, N.; Nakayama, K.; Yagi, K.; Yanagisawa, M.; Emoto, N. ET-1 from endothelial cells is required for complete angiotensin II-induced cardiac fibrosis and hypertrophy. Life Sci. 2012, 91, 651–657. [Google Scholar] [CrossRef] [Green Version]
  29. Abraham, D. Role of endothelin in lung fibrosis. Eur. Respir. Rev. 2008, 17, 145–150. [Google Scholar]
  30. Meng, X.M.; Nikolic-Paterson, D.J.; Lan, H.Y. TGF-β: The master regulator of fibrosis. Nat. Rev. Nephrol. 2016, 12, 325–338. [Google Scholar] [CrossRef]
  31. Rodríguez-Pascual, F.; Busnadiego, O.; González-Santamaría, J. The profibrotic role of endothelin-1: Is the door still open for the treatment of fibrotic diseases? Life Sci. 2014, 118, 156–164. [Google Scholar] [CrossRef] [Green Version]
  32. Yang, X.; Chen, B.; Liu, T.; Chen, X. Reversal of myofibroblast differentiation: A review. Eur. J. Pharmacol. 2014, 734, 83–90. [Google Scholar] [CrossRef]
  33. Parichatikanond, W.; Luangmonkong, T.; Mangmool, S.; Kurose, H. Therapeutic targets for the treatment of cardiac fibrosis and cancer: Focusing on TGF-β signaling. Front. Cardiovasc. Med. 2020, 7, 34. [Google Scholar] [CrossRef]
  34. Schieffer, B.; Wirger, A.; Meybrunn, M.; Seitz, S.; Holtz, J.; Riede, U.N.; Drexler, H. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat. Circulation 1994, 89, 2273–2282. [Google Scholar] [CrossRef] [Green Version]
  35. Regan, C.P.; Anderson, P.G.; Bishop, S.P.; Berecek, K.H. Pressure-independent effects of AT1-receptor antagonism on cardiovascular remodeling in aortic-banded rats. Am. J. Physiol. Heart. Circ. Physiol. 1997, 272, H2131–H2138. [Google Scholar] [CrossRef]
  36. Luchtefeld, M.; Drexler, H.; Schieffer, B. Role of Gbeta-subunit in angiotensin II-type 1 receptor signaling. Biochem. Biophys. Res. Commun. 2001, 280, 756–760. [Google Scholar] [CrossRef]
  37. Schultz, J.E.J.; Witt, S.A.; Glascock, B.J.; Nieman, M.L.; Reiser, P.J.; Nix, S.L.; Kimball, T.R.; Doetschman, T. TGF-β1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J. Clin. Invest. 2002, 109, 787–796. [Google Scholar] [CrossRef]
  38. Akhurst, R.J.; Padgett, R.W. Matters of context guide future research in TGFβ superfamily signaling. Sci. Signal. 2015, 8, re10. [Google Scholar] [CrossRef] [Green Version]
  39. Gao, X.; He, X.; Luo, B.; Peng, L.; Lin, J.; Zuo, Z. Angiotensin II increases collagen I expression via transforming growth factor-beta1 and extracellular signal-regulated kinase in cardiac fibroblasts. Eur. J. Pharmacol. 2009, 606, 115–120. [Google Scholar] [CrossRef]
  40. Yamamoto, K.; Masuyama, T.; Sakata, Y.; Mano, T.; Nishikawa, N.; Kondo, H.; Akehi, N.; Kuzuya, T.; Miwa, T.; and Hori, M. Roles of renin-angiotensin and endothelin systems in development of diastolic heart failure in hypertensive hearts. Cardiovasc. Res. 2000, 47, 274–283. [Google Scholar] [CrossRef] [Green Version]
  41. Abraham, D.J.; Vancheeswaran, R.; Dashwood, M.R.; Rajkumar, V.S.; Pantelides, P.; Xu, S.W.; du Bois, R.M.; Black, C.M. Increased levels of endothelin-1 and differential endothelin type A and B receptor expression in scleroderma-associated fibrotic lung disease. Am. J. Pathol. 1997, 151, 831. [Google Scholar]
  42. Davie, N.; Haleen, S.J.; Upton, P.D.; Polak, J.M.; Yacoub, M.H.; Morrell, N.W.; Wharton, J. ETA and ETB receptors modulate the proliferation of human pulmonary artery smooth muscle cells. Am. J. Respir. Crit. Care Med. 2002, 165, 398–405. [Google Scholar] [CrossRef]
  43. Sun, Y.; Zhang, J.Q.; Zhang, J.; Ramires, F.J. Angiotensin II, transforming growth factor-β1 and repair in the infarcted heart. J. Mol. Cell. Cardiol. 1998, 30, 1559–1569. [Google Scholar] [CrossRef]
  44. Imai, T.; Hirata, Y.; Emori, T.; Yanagisawa, M.; Masaki, T.; Marumo, F. Induction of endothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension 1992, 19, 753–757. [Google Scholar] [CrossRef] [Green Version]
  45. Sung, C.P.; Arleth, A.J.; Storer, B.L.; Ohlstein, E.H. Angiotensin type 1 receptors mediate smooth muscle proliferation and endothelin biosynthesis in rat vascular smooth muscle. J. Pharmacol. Exp. Ther. 1994, 271, 429–437. [Google Scholar]
  46. Shi-Wen, X.; Rodríguez-Pascual, F.; Lamas, S.; Holmes, A.; Howat, S.; Pearson, J.D.; Dashwood, M.R.; du Bois, R.M.; Denton, C.P.; Black, C.M.; et al. Constitutive ALK5-independent c-Jun N-terminal kinase activation contributes to endothelin-1 overexpression in pulmonary fibrosis: Evidence of an autocrine endothelin loop operating through the endothelin A and B receptors. Molecular and cellular biology. Mol. Cell. Biol. 2006, 26, 5518–5527. [Google Scholar] [CrossRef] [Green Version]
  47. Garrison, G.; Huang, S.K.; Okunishi, K.; Scott, J.P.; Kumar Penke, L.R.; Scruggs, A.M.; Peters-Golden, M. Reversal of myofibroblast differentiation by prostaglandin E2. Am. J. Respir. Cell. Mol. Biol. 2013, 48, 550–558. [Google Scholar] [CrossRef] [Green Version]
  48. Rangarajan, S.; Bone, N.B.; Zmijewska, A.A.; Jiang, S.; Park, D.W.; Bernard, K.; Locy, M.L.; Ravi, S.; Deshane, J.; Mannon, R.B.; et al. Metformin reverses established lung fibrosis in a bleomycin model. Nat. Med. 2018, 24, 1121–1127. [Google Scholar] [CrossRef]
  49. Duangrat, R.; Parichatikanond, W.; Likitnukul, S.; Mangmool, S. Endothelin-1 induces cell proliferation and myofibroblast differentiation through the ETAR/Gαq/ERK signaling pathway in human cardiac fibroblasts. Int. J. Mol. Sci. 2023, 24, 4475. [Google Scholar] [CrossRef]
  50. Phosri, S.; Bunrukchai, K.; Parichatikanond, W.; Sato, V.H.; Mangmool, S. Epac is required for exogenous and endogenous stimulation of adenosine A2B receptor for inhibition of angiotensin II-induced collagen synthesis and myofibroblast differentiation. Purinergic Signal 2018, 14, 141–156. [Google Scholar] [CrossRef]
  51. Mangmool, S.; Kyaw, E.T.H.; Nuamnaichati, N.; Pandey, S.; Parichatikanond, W. Stimulation of adenosine A1 receptor prevents oxidative injury in H9c2 cardiomyoblasts: Role of Gβγ-mediated Akt and ERK1/2 signaling. Toxicol. Appl. Pharmacol. 2022, 451, 116175. [Google Scholar] [CrossRef]
  52. Nuamnaichati, N.; Sato, V.H.; Moongkarndi, P.; Parichatikanond, P.; Mangmool, S. Sustained β-AR stimulation induces synthesis and secretion of growth factors in cardiac myocytes that affect on cardiac fibroblast activation. Life Sci. 2018, 193, 257–269. [Google Scholar] [CrossRef]
Ijms 24 06972 g001 550
Figure 1. Blockade of AT1R and Gαq protein antagonizes Ang II-induced myofibroblast differentiation. Serum-starved adult HCFs were pretreated with valsartan (valsar; 1 µM), FR900359 (Gαq inh; 1 µM), or gallein (Gβγ inh; 10 µM) for 1 h before stimulation with 200 nM Ang II for 6 h (A) or 24 h (B,C). (A) Relative mRNA levels of fibrotic markers, α-SMA and collagen I, were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B) and stress fiber formation (red) (C). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Figure 1. Blockade of AT1R and Gαq protein antagonizes Ang II-induced myofibroblast differentiation. Serum-starved adult HCFs were pretreated with valsartan (valsar; 1 µM), FR900359 (Gαq inh; 1 µM), or gallein (Gβγ inh; 10 µM) for 1 h before stimulation with 200 nM Ang II for 6 h (A) or 24 h (B,C). (A) Relative mRNA levels of fibrotic markers, α-SMA and collagen I, were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B) and stress fiber formation (red) (C). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Ijms 24 06972 g001
Ijms 24 06972 g002 550
Figure 2. The synergistic function of TGF-β and ET-1 is required for Ang II-induced myofibroblast differentiation. Serum-starved adult HCFs were pretreated with valsartan (valsar; 1 µM), LY2109761 (TGF-β inh; 5 µM), bosentan (1 µM), or LY2109761 plus bosentan for 1 h before stimulation with 200 nM Ang II for 6 h (A) or 24 h (B,C). (A) Relative mRNA levels of fibrotic markers, α-SMA and collagen I, were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B) and stress fiber formation (red) (C). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Figure 2. The synergistic function of TGF-β and ET-1 is required for Ang II-induced myofibroblast differentiation. Serum-starved adult HCFs were pretreated with valsartan (valsar; 1 µM), LY2109761 (TGF-β inh; 5 µM), bosentan (1 µM), or LY2109761 plus bosentan for 1 h before stimulation with 200 nM Ang II for 6 h (A) or 24 h (B,C). (A) Relative mRNA levels of fibrotic markers, α-SMA and collagen I, were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B) and stress fiber formation (red) (C). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Ijms 24 06972 g002
Ijms 24 06972 g003 550
Figure 3. ET-1 is a downstream effector of TGF-β1, and blockade of either Smad or ERK1/2 activities attenuates profibrotic effects of TGF-β1. (A–C) Serum-starved adult HCFs were pretreated with LY2109761 (TGF-β inh; 5 µM), bosentan (1 µM), or valsartan (valsar; 1 µM) for 1 h before treatment with 1 ng/mL TGF-β1 for 6 h (A) or 24 h (B,C). (D–F) Serum-starved adult HCFs were pretreated with 1 µM Smad inhibitor (Smad inh), 1 µM FR180204 (ERK inhibitor; ERK inh), 1 µM SB203580 (p38 MAPK inhibitor; p38 inh), or Smad inh plus ERK inh for 1 h before treatment with 1 ng/mL TGF-β1 for 6 h (D) or 24 h (E,F). (A,D) Relative mRNA levels of fibrotic markers, α-SMA and collagen I, were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B,E) and stress fiber formation (red) (C,F). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. TGF-β1.
Figure 3. ET-1 is a downstream effector of TGF-β1, and blockade of either Smad or ERK1/2 activities attenuates profibrotic effects of TGF-β1. (A–C) Serum-starved adult HCFs were pretreated with LY2109761 (TGF-β inh; 5 µM), bosentan (1 µM), or valsartan (valsar; 1 µM) for 1 h before treatment with 1 ng/mL TGF-β1 for 6 h (A) or 24 h (B,C). (D–F) Serum-starved adult HCFs were pretreated with 1 µM Smad inhibitor (Smad inh), 1 µM FR180204 (ERK inhibitor; ERK inh), 1 µM SB203580 (p38 MAPK inhibitor; p38 inh), or Smad inh plus ERK inh for 1 h before treatment with 1 ng/mL TGF-β1 for 6 h (D) or 24 h (E,F). (A,D) Relative mRNA levels of fibrotic markers, α-SMA and collagen I, were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B,E) and stress fiber formation (red) (C,F). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. TGF-β1.
Ijms 24 06972 g003
Ijms 24 06972 g004 550
Figure 4. ET-1 acts as a downstream effector of Ang II and TGF-β1, which induces α-SMA and collagen I expression and stress fiber formation through the ETARs. (A–C) Serum-starved adult HCFs were incubated with LY2109761 (TGF-β inh; 5 µM), bosentan (1 µM), or valsartan (valsar; 1 µM) for 1 h before stimulation with 20 nM ET-1 for 6 h (A) or 24 h (B,C). (D–F) Serum-starved adult HCFs were pretreated with 1 µM ambrisentan (ambri; ETAR antagonist) or 1 µM BQ788 (ETBR antagonist) for 1 h before stimulation with 20 nM ET-1 for 6 h (D) or 24 h (E,F). (A,D) Relative mRNA levels of fibrotic markers, α-SMA, and collagen I were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B,E) and stress fiber formation (red) (C,F). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Figure 4. ET-1 acts as a downstream effector of Ang II and TGF-β1, which induces α-SMA and collagen I expression and stress fiber formation through the ETARs. (A–C) Serum-starved adult HCFs were incubated with LY2109761 (TGF-β inh; 5 µM), bosentan (1 µM), or valsartan (valsar; 1 µM) for 1 h before stimulation with 20 nM ET-1 for 6 h (A) or 24 h (B,C). (D–F) Serum-starved adult HCFs were pretreated with 1 µM ambrisentan (ambri; ETAR antagonist) or 1 µM BQ788 (ETBR antagonist) for 1 h before stimulation with 20 nM ET-1 for 6 h (D) or 24 h (E,F). (A,D) Relative mRNA levels of fibrotic markers, α-SMA, and collagen I were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). After treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B,E) and stress fiber formation (red) (C,F). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. ET-1.
Ijms 24 06972 g004
Ijms 24 06972 g005 550
Figure 5. Ang II induces the secretion and synthesis of TGF-β1 and ET-1 via the AT1R/Gαq axis in adult HCFs. Serum-starved adult HCFs were incubated with valsartan (valsar; 1 µM), PD123319 (1 µM), FR900359 (Gαq inh; 1 µM), or LY2109761 (TGF-β inh; 5 µM) for 1 h before stimulation with 200 nM Ang II for 24 (A) or 6 h (B). (A) After Ang II treatment, the culture medium was collected. The amounts of TGF-β1 and ET-1 secreted into the culture medium were determined by ELISA. (B) Relative mRNA levels of TGF-β1 and ET-1 were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Figure 5. Ang II induces the secretion and synthesis of TGF-β1 and ET-1 via the AT1R/Gαq axis in adult HCFs. Serum-starved adult HCFs were incubated with valsartan (valsar; 1 µM), PD123319 (1 µM), FR900359 (Gαq inh; 1 µM), or LY2109761 (TGF-β inh; 5 µM) for 1 h before stimulation with 200 nM Ang II for 24 (A) or 6 h (B). (A) After Ang II treatment, the culture medium was collected. The amounts of TGF-β1 and ET-1 secreted into the culture medium were determined by ELISA. (B) Relative mRNA levels of TGF-β1 and ET-1 were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Ijms 24 06972 g005
Ijms 24 06972 g006 550
Figure 6. TGF-β1 induces the secretion and production of ET-1 via Smad- and ERK1/2-dependent pathways. Serum-starved adult HCFs were pretreated with 1 µM Smad inhibitor (Smad inh), 1 µM FR180204 (ERK inhibitor; ERK inh), or 1 µM SB203580 (p38 MAPK inhibitor; p38 inh) for 1 h before treatment with 1 ng/mL TGF-β1 for 24 (A) or 6 h (B). (A) After TGF-β1 treatment, the culture medium was collected. The amounts of ET-1 secreted into the culture medium were determined by ELISA. (B) Relative mRNA levels of ET-1 were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. TGF-β1.
Figure 6. TGF-β1 induces the secretion and production of ET-1 via Smad- and ERK1/2-dependent pathways. Serum-starved adult HCFs were pretreated with 1 µM Smad inhibitor (Smad inh), 1 µM FR180204 (ERK inhibitor; ERK inh), or 1 µM SB203580 (p38 MAPK inhibitor; p38 inh) for 1 h before treatment with 1 ng/mL TGF-β1 for 24 (A) or 6 h (B). (A) After TGF-β1 treatment, the culture medium was collected. The amounts of ET-1 secreted into the culture medium were determined by ELISA. (B) Relative mRNA levels of ET-1 were analyzed by qRT-PCR. Data are expressed as the mean ± SEM (n = 4). * p < 0.05 vs. vehicle; # p < 0.05 vs. TGF-β1.
Ijms 24 06972 g006
Ijms 24 06972 g007 550
Figure 7. Restorative effects of ARB, TGF-β inhibitor, and ERA on Ang II-induced myofibroblast differentiation. (A) Experimental design and timeline of the treatment in cultured adult HCFs. (B,C) Fibroblasts were treated with 200 nM Ang II for 24 h to activate fibroblast-to-myofibroblast transformation. After 24 h, cells were replaced with media containing Ang II with different inhibitors, including valsartan, LY2109761, bosentan, and LY2109761 plus bosentan for up to 3 days. Analysis was performed on days 1 or 3 after cotreatment. At the end of treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B) and stress fiber formation (red) (C). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Figure 7. Restorative effects of ARB, TGF-β inhibitor, and ERA on Ang II-induced myofibroblast differentiation. (A) Experimental design and timeline of the treatment in cultured adult HCFs. (B,C) Fibroblasts were treated with 200 nM Ang II for 24 h to activate fibroblast-to-myofibroblast transformation. After 24 h, cells were replaced with media containing Ang II with different inhibitors, including valsartan, LY2109761, bosentan, and LY2109761 plus bosentan for up to 3 days. Analysis was performed on days 1 or 3 after cotreatment. At the end of treatment, immunofluorescence staining was used to determine α-SMA expression (green) (B) and stress fiber formation (red) (C). Nuclei were stained with DAPI (blue). Scale bar, 10 μm. Data are expressed as the mean ± SEM (n = 3). * p < 0.05 vs. vehicle; # p < 0.05 vs. Ang II.
Ijms 24 06972 g007
Ijms 24 06972 g008 550
Figure 8. Schematic representing the TGF-β1, ET-1 and Ang II networking on myofibroblast differentiation. In adult HCFs, Ang II stimulation of AT1Rs lead to an upregulation of TGF-β1 and ET-1 and activation of their effectors through the AT1R/Gαq axis. The activated AT1Rs transduce the signal through TGF-β1 cascade, which in turn upregulates ET-1 through the Smad-dependent and ERK1/2-dependent pathways. The elevated ET-1 then binds to and activates ETARs, leading to increases in collagen I and α-SMA synthesis and stress fiber formation. Interestingly, antagonism of AT1Rs and dual blockade of TGF-β1 receptors and ETRs exhibit antifibrotic effects by prevention and restoration of myofibroblast differentiation induced by Ang II. α-SMA: α-smooth muscle actin; Ang II: angiotensin II; AT1R: angiotensin II receptor type 1; ARB: angiotensin II receptor blocker; ET-1: Endothelin-1; ERAs: endothelin receptor antagonists; TβR I/II: TGF-β receptor type I and II.
Figure 8. Schematic representing the TGF-β1, ET-1 and Ang II networking on myofibroblast differentiation. In adult HCFs, Ang II stimulation of AT1Rs lead to an upregulation of TGF-β1 and ET-1 and activation of their effectors through the AT1R/Gαq axis. The activated AT1Rs transduce the signal through TGF-β1 cascade, which in turn upregulates ET-1 through the Smad-dependent and ERK1/2-dependent pathways. The elevated ET-1 then binds to and activates ETARs, leading to increases in collagen I and α-SMA synthesis and stress fiber formation. Interestingly, antagonism of AT1Rs and dual blockade of TGF-β1 receptors and ETRs exhibit antifibrotic effects by prevention and restoration of myofibroblast differentiation induced by Ang II. α-SMA: α-smooth muscle actin; Ang II: angiotensin II; AT1R: angiotensin II receptor type 1; ARB: angiotensin II receptor blocker; ET-1: Endothelin-1; ERAs: endothelin receptor antagonists; TβR I/II: TGF-β receptor type I and II.
Ijms 24 06972 g008
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Duangrat, R.; Parichatikanond, W.; Mangmool, S. Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of AT1R/Gαq-Mediated TGF-β1 and ET-1 Signaling. Int. J. Mol. Sci. 2023, 24, 6972. https://doi.org/10.3390/ijms24086972

AMA Style

Duangrat R, Parichatikanond W, Mangmool S. Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of AT1R/Gαq-Mediated TGF-β1 and ET-1 Signaling. International Journal of Molecular Sciences. 2023; 24(8):6972. https://doi.org/10.3390/ijms24086972

Chicago/Turabian Style

Duangrat, Ratchanee, Warisara Parichatikanond, and Supachoke Mangmool. 2023. "Dual Blockade of TGF-β Receptor and Endothelin Receptor Synergistically Inhibits Angiotensin II-Induced Myofibroblast Differentiation: Role of AT1R/Gαq-Mediated TGF-β1 and ET-1 Signaling" International Journal of Molecular Sciences 24, no. 8: 6972. https://doi.org/10.3390/ijms24086972

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop